Section Arrow
ASND.NASDAQ
- Ascendis Pharma A/S
Quotes are at least 15-min delayed:2026/03/06 04:00 EST
Pre Market
Last
 --
-- (--)
Bid
219
Ask
2,370.39
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 237.35
-4.1 (-1.70%)
Day High 
240.77 
Prev. Close
241.45 
1-M High
248.6 
Volume 
535.80K 
Bid
219
Ask
2,370.39
Day Low
234.88 
Open
238.51 
1-M Low
211 
Market Cap 
14.83B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 233.83 
20-SMA 227.5 
50-SMA 220.72 
52-W High 248.6 
52-W Low 124.06 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.76/14.31
Enterprise Value
15.22B
Balance Sheet
Book Value Per Share
-3.12
Cash Flow
Cash Flow Yield
0.00
Income Statement
Total Revenue
720.13M
Operating Revenue Per Share
2.62
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
QNCXQuince Therapeutics0.1094+0.0054+5.19%-- 
Pre Market 0.1103 +0.0055 +5.25%
IBOImpact BioMedical Inc.0.6425+0.2292+55.46%-- 
Pre Market 0.588 -0.0545 -8.48%
TNYATenaya Therapeutics0.8193+0.2304+39.12%-- 
Pre Market 0.8345 +0.01495 +1.82%
IOVAIovance Biotherapeutics4.58+0.34+8.02%-- 
Pre Market 4.68 +0.085 +1.85%
GOSSGossamer Bio0.5218-0.0579-9.99%-- 
Pre Market 0.5295 +0.0077 +1.48%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.